bluuebunny/crossref_metadata_2025 huggingface dataset:
Progress and Challenges in the Field of Snakebite Envenoming Therapeutics
Authors: Gutiérrez José María , R. Casewell Nicholas , Laustsen Andreas H.
Published: August 2024

Snakebite envenoming kills and maims hundreds of thousands of people every year, especially in the rural settings of tropical regions. Envenomings are still treated with animal-derived antivenoms, which have prevented many lives from being lost but which are also medicines in need of innovation. Strides are being made to improve envenoming therapies, with promising efforts made toward optimizing manufacturing and quality aspects of existing antivenoms, accelerating research and development of recombinant antivenoms based on monoclonal antibodies, and repurposing of small-molecule inhibitors that block key toxins. Here, we review the most recent advances in these fields and discuss therapeutic opportunities and limitations for different snakebite treatment modalities. Finally, we discuss challenges related to preclinical and clinical evaluation, regulatory pathways, large-scale manufacture, and distribution and access that need to be addressed to fulfill the goals of the World Health Organization's global strategy to prevent and control snakebite envenoming.
In Vitro Proinflammatory and Cytotoxic Activity of Chicken‐and Turkey‐Based Würstels: A Preliminary Report
Authors: Corsi Lorenzo , Rubattu Nicola , Salis Severyn , Magi Gian Enrico , Tinelli Antonella , Cocco Raffaella , Alagawany Mahmoud , Cornejo Javiera , Marini Carlotta , Vitturini Claudia , Stocchi Roberta , Rea Stefano , Loschi Anna Rita , Sabia Carla , Di Cerbo Alessandro
Published: August 2024

Ultraprocessed foods represent a severe concern to human health due to their direct link with metabolic diseases. Among these foods, mechanically separated meat‐based products are of particular interest due to the use of preservatives and the possible presence of antibiotic residues free or bound to animals’ bone fragments. To demonstrate the potential harmfulness of these substances, 28 samples of commercially available würstels of different suppliers, price category, package size, and produced with mechanically separated chicken and turkey meat were randomly collected from the Italian market. The presence of antibiotics was assessed by LC/HRMS; bone fragments were identified using histological, histochemical, and microscopical analyses; the cytotoxic and proinflammatory activity of the würstels and their ingredients was assessed using ELISA. Bone fragments were detected in all samples, while only 9 out of 28 samples were positive for the presence of doxycycline, although at concentrations far from the maximum residue limits, ranging from 0.36 to 2.50 ug/kg. Most of the samples were cytotoxic at a dilution of 1 : 20 while all of the 3 tested exerted a proinflammatory effect, with significant cytokines’ release (IL‐1α, IL‐1β, IL‐6, IL‐8, INF‐γ, TNF‐α, GM‐CSF, and MCAF) at 24 and 36 h ( ∗∗∗P < 0.001). Part of the cytokine release was due to the presence of beech‐ and oak‐based smoke flavoring, where a significant release of IL‐1β ( ∗∗∗P < 0.001), IL‐8 ( ∗∗∗P < 0.001,  ∗∗P < 0.01), INF‐γ ( ∗P < 0.05 and  ∗∗P < 0.01), and MCAF ( ∗∗∗P < 0.001) was observed at 12 and/or 24 h. Although the results need further investigation to elucidate the cytotoxic and proinflammatory process, this can be considered one of the first reports shedding light on the possible toxic potential of some substances routinely used in food processing, even at allowed concentrations. Moreover, it provides new insights into the understanding of the link between high consumption of ultraprocessed meat, increased risk of inflammation, and progression of chronic diseases.
Triangular Function Method is Adopted to Solve Nonlinear Stochastic It o∧–Volterra Integral Equations
Authors: Jiang Guo , Chen Dan , Liu Fugang
Published: August 2024

This article presents the numerical solutions of nonlinear stochastic It –Volterra integral equations by using the basis function method under the global Lipschitz condition. Integral operator matrixes of triangular functions are used to convert the nonlinear stochastic integral equations into a system of algebraic equations. Meanwhile, we gain the error of the current method, and it is demonstrated that the error accuracy of this method is higher than that of the BPFs. In the end, the feasibility, accuracy, and validity of the current method are demonstrated by numerical results.
Predictive Value of Serum CIRP in Acute Kidney Injury after Total Aortic Arch Replacement
Authors: Chen Ke , Wang Dongxu , Fang Minhua , Wang Pengyu , Hou Peng , Liu Yu , Yu Liming , Zhou Zijun , Gao Juan , Zhang Yong
Published: August 2024

Objectives. To investigate the predictive value of serum cold‐inducible RNA‐binding protein (CIRP) and postoperative acute kidney injury (AKI) after total aortic arch replacement. Methods. Eighty‐six patients with acute Stanford type A aortic dissection (ATAAD) admitted to hospital from October 2019 to February 2021 were retrospectively selected as the study subjects. All patients underwent total aortic arch replacement under moderate hypothermic circulatory arrest (MHCA) with selective antegrade cerebral perfusion (SACP). Detection of the level of serum CIRP after admission and perioperative clinical data of patients were collected and analyzed. Kidney Disease: Improving Global Outcomes (KDIGO) criteria were used to stage renal function. Patients were divided into a non‐AKI‐3 group (n = 70) and an AKI‐3 group (n = 16) according to the stage of postoperative renal function. The risk factors for postoperative AKI KDIGO stage 3 were analyzed by a multivariate logistic regression model. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy. Results. In 86 patients, postoperative AKI‐3 stage accounted for 18.6% (16/86). Compared with the non‐AKI‐3 group, the AKI‐3 group had a higher preoperative BMI index, C‐reactive protein, and CIRP level; a longer intraoperative cooling time, cardiopulmonary bypass time, and aortic cross‐clamping time; and a higher intraoperative coronary artery bypass ratio (all P < 0.05). Multivariate logistic regression results showed that CIRP (OR = 1.001, 95% CI: 1.000–1.002, P = 0.012) was an independent risk factor for postoperative AKI KDIGO stage 3. Conclusion. The serum CIRP is associated with postoperative acute kidney injury after total aortic arch replacement in ATAAD patients and may serve as a predictive indicator for early detection and intervention to improve the prognosis.
Enhancing Lysostaphin Thermostability and Utilizing Lysostaphin‐Producing Probiotics to Combat Staphylococcus aureus in Milk
Authors: Zhang Shuhang , Wen Kangshu , Song Wenxia , Li Qingbin , Qi Qingsheng , Lu Xuemei
Published: August 2024

The emergence and spread of methicillin‐resistant Staphylococcus aureus (MRSA) is a major cause of bacterial infections in healthcare. Lysostaphin, a Zn2+‐dependent endopeptidase, hydrolyzes the glycine (G)‐linked pentapeptide bridge in the pathogen Staphylococcus aureus. In this study, the stability of lysostaphin was improved by engineering the addition of disulfide bonds around the protein’s Zn2+ binding site through molecular dynamics simulation. Further mutagenesis to add polyG at the C‐terminus yielded combination variant 319/252‐G3, which was 2.6‐fold more stable than lysostaphin after 30 min at 60°C. Optimization of the C‐terminal glycine number produced variant 319/252‐G6, which retained 67.3% of its antimicrobial activity after 30 min at 70°C, and could be resistant to milk pasteurization conditions. Based on this, a probiotic strain of Escherichia coli Nissle 1917 to constitutively express and secrete lysostaphin from a mutated lac operator was engineered, resulting in effective control and prevention of S. aureus contamination in milk. One possible biotechnological application to utilize lysostaphin and probiotic strains can be used in animal feed and food additives for the prevention and treatment of S. aureus infections.
Figure S5 from Estrogen Induces LCAT to Maintain Cholesterol Homeostasis and Suppress Hepatocellular Carcinoma Development
Authors: He Wenzhi , Wang Min , Zhang Xuechun , Wang Yilan , Zhao Dongli , Li Wenhua , Lei Fang , Peng Min , Zhang Zhonglin , Yuan Yufeng , Huang Zan
Published: August 2024

Supplementary Figure 5
Supplementary Figure S4 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Authors: Kunkel Mark W. , Coussens Nathan P. , Morris Joel , Taylor Ronald C. , Dexheimer Thomas S. , Jones Eric M. , Doroshow James H. , Teicher Beverly A.
Published: August 2024

Correlation plots EGFR-targeting agents.
Supplementary Video 4 from Human 3D Ovarian Cancer Models Reveal Malignant Cell–Intrinsic and –Extrinsic Factors That Influence CAR T-cell Activity
Authors: Joy Joash D. , Malacrida Beatrice , Laforêts Florian , Kotantaki Panoraia , Maniati Eleni , Manchanda Ranjit , Annibaldi Alessandro , Hopkins Sarah , Garrobo-Calleja Ianire , Gautrot Julien , Balkwill Frances R.
Published: August 2024

Behavior of CAR-T cells in G164/FB gels with TGFβ-R inhi
Supplementary Video 2 from Human 3D Ovarian Cancer Models Reveal Malignant Cell–Intrinsic and –Extrinsic Factors That Influence CAR T-cell Activity
Authors: Joy Joash D. , Malacrida Beatrice , Laforêts Florian , Kotantaki Panoraia , Maniati Eleni , Manchanda Ranjit , Annibaldi Alessandro , Hopkins Sarah , Garrobo-Calleja Ianire , Gautrot Julien , Balkwill Frances R.
Published: August 2024

Behavior of CAR-T cells in G164/FB gels
Supplementary Figure 2 from Human 3D Ovarian Cancer Models Reveal Malignant Cell–Intrinsic and –Extrinsic Factors That Influence CAR T-cell Activity
Authors: Joy Joash D. , Malacrida Beatrice , Laforêts Florian , Kotantaki Panoraia , Maniati Eleni , Manchanda Ranjit , Annibaldi Alessandro , Hopkins Sarah , Garrobo-Calleja Ianire , Gautrot Julien , Balkwill Frances R.
Published: August 2024

OvCAR3 cells were sensitive but G164 cells were resistant to CAR-T cell cytotoxicity in monolayer cultures.
Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Authors: Keller Patricia J. , Adams Elizabeth J. , Wu Rentian , Côté Alexandre , Arora Shilpi , Cantone Nico , Meyer Rosana , Mertz Jennifer A. , Gehling Victor , Cui Jike , Stuckey Jacob I. , Khanna Avinash , Zhao Feng , Chen Zehua , Yu Ziyang , Cummings Richard T. , Taimi Mohammed , Lakhani Nehal J. , Rasco Drew , Gutierrez Martin , Duska Linda , Devitt Michael , Rippley Ronda , Levell Julian , Truong Jennifer , Wang Jing , Sun Kaiming , Trojer Patrick
Published: August 2024

List of 365 genes (used in main Fig. 7F) that are induced in patient’s whole blood upon treatment with tulmimetostat
Suppl Table 1 from Extracellular Vesicles Containing circMYBL1 Induce CD44 in Adenoid Cystic Carcinoma Cells and Pulmonary Endothelial Cells to Promote Lung Metastasis
Authors: Fu Min , Gao Qian , Xiao Mian , Li Rui-Feng , Sun Xin-Yi , Li Sheng-Lin , Peng Xin , Ge Xi-Yuan
Published: August 2024

The used primers, siRNAs, and probes
Supplementary Table S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Authors: Keller Patricia J. , Adams Elizabeth J. , Wu Rentian , Côté Alexandre , Arora Shilpi , Cantone Nico , Meyer Rosana , Mertz Jennifer A. , Gehling Victor , Cui Jike , Stuckey Jacob I. , Khanna Avinash , Zhao Feng , Chen Zehua , Yu Ziyang , Cummings Richard T. , Taimi Mohammed , Lakhani Nehal J. , Rasco Drew , Gutierrez Martin , Duska Linda , Devitt Michael , Rippley Ronda , Levell Julian , Truong Jennifer , Wang Jing , Sun Kaiming , Trojer Patrick
Published: August 2024

Table with antibody source information including RRID if available
Figure S4 from Extracellular Vesicles Containing circMYBL1 Induce CD44 in Adenoid Cystic Carcinoma Cells and Pulmonary Endothelial Cells to Promote Lung Metastasis
Authors: Fu Min , Gao Qian , Xiao Mian , Li Rui-Feng , Sun Xin-Yi , Li Sheng-Lin , Peng Xin , Ge Xi-Yuan
Published: August 2024

Figure S4
Figure S3 from Extracellular Vesicles Containing circMYBL1 Induce CD44 in Adenoid Cystic Carcinoma Cells and Pulmonary Endothelial Cells to Promote Lung Metastasis
Authors: Fu Min , Gao Qian , Xiao Mian , Li Rui-Feng , Sun Xin-Yi , Li Sheng-Lin , Peng Xin , Ge Xi-Yuan
Published: August 2024

Figure S3
Figure S4 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Authors: Ma Hua , Esfahani Shadi A. , Krishna Shriya , Ataeinia Bahar , Zhou Iris Y. , Rotile Nicholas J. , Weigand-Whittier Jonah , Boice Avery T. , Liss Andrew S. , Tanabe Kenneth K. , Caravan Peter
Published: August 2024

Figure S4. The PDAC6 tumor percentage change of normalized signal intensity (%nSI, normalized to an adjacent phantom) at 30 min p.i. of probe (n = 4 for each group). One-way ANOVA with Tukey’s post hoc test, *P<0.05, **P < 0.01, ns, not significant.
Supplemental Figure 6 from Age-Specific Cancer Mortality in the US During the COVID-19 Pandemic, March to December 2020
Authors: Shiels Meredith S. , Haque Anika T. , Freedman Neal D. , Kim Hae-Rin , Berrington de González Amy , Albert Paul S.
Published: August 2024

Supplemental Figure 6. Adjusted rate ratios comparing female breast cancer death rates during the COVID-19 period (March-December 2020) to the pre-COVID-19 period (January 2011-February 2020) by month by age group. Points represent adjusted rate ratios and lines represent 95% confidence intervals. Models adjusted for linear calendar time in months, and seasonal patterns with sine and cosine terms.
Supplemental Figure 5 from Age-Specific Cancer Mortality in the US During the COVID-19 Pandemic, March to December 2020
Authors: Shiels Meredith S. , Haque Anika T. , Freedman Neal D. , Kim Hae-Rin , Berrington de González Amy , Albert Paul S.
Published: August 2024

Supplemental Figure 5. Adjusted rate ratios comparing pancreatic cancer death rates during the COVID-19 period (March-December 2020) to the pre-COVID-19 period (January 2011-February 2020) by month by age group. Points represent adjusted rate ratios and lines represent 95% confidence intervals. Models adjusted for linear calendar time in months, and seasonal patterns with sine and cosine terms.
Supplemental Figure 1 from Age-Specific Cancer Mortality in the US During the COVID-19 Pandemic, March to December 2020
Authors: Shiels Meredith S. , Haque Anika T. , Freedman Neal D. , Kim Hae-Rin , Berrington de González Amy , Albert Paul S.
Published: August 2024

Supplemental Figure 1. Age-specific observed (blue points) and fitted (red line) monthly cancer mortality rates in the U.S., 2011-2020, accounting for both temporal and seasonal patterns.
Supplementary Table S1 from Adverse Childhood Experiences, Resilience, and Cardiovascular Disease in Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Authors: Schwartz Lindsay F. , Stratton Kayla L. , Leisenring Wendy M. , Rodriguez Stefania M. , Alston Shani , McDonald Aaron , Vukadinovich Chris , Rinehardt Dayton , Oeffinger Kevin C. , Chow Eric J. , Krull Kevin R. , Brinkman Tara M. , Nathan Paul C. , Tan Marcia M. , McCrae Julie S. , Burkhardt Tiffany , Ness Kirsten K. , Armstrong Gregory T. , Henderson Tara O.
Published: August 2024

Demographic and treatment characteristics of eligible childhood cancer survivors
Supplementary Figure S5 from Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms
Authors: Davidson Natalie R. , Barnard Mollie E. , Hippen Ariel A. , Campbell Amy , Johnson Courtney E. , Way Gregory P. , Dalley Brian K. , Berchuck Andrew , Salas Lucas A. , Peres Lauren C. , Marks Jeffrey R. , Schildkraut Joellen M. , Greene Casey S. , Doherty Jennifer A.
Published: August 2024

Balanced accuracy heatmap
Supplementary table 1 from Understanding Benign Breast Disease and Subsequent Breast Cancer in Hispanic White Females: A Step Closer to Evidence-Based Management
Authors: Lohani Kush R. , Nibbe Andrea M. , Vierkant Robert A. , Pacheco-Spann Laura M. , Seymour Lisa R. , Vachon Celine M. , Sherman Mark E. , Winham Stacey J. , Degnim Amy C. , Hill Deirdre A.
Published: August 2024

Studies on benign breast disease in different races / ethnicities.
Supplementary Table 2 from Assessing the Relationship between Biomarkers of Exposure and Biomarkers of Potential Harm: PATH Study Wave 1 (2013 to 2014)
Authors: Chang Cindy M. , Thakur Sapna , Montes de Oca Ruben , Rostron Brian L. , Cheng Yu-Ching , Wright M. Jerry , van Bemmel Dana M. , Wang Lanqing , Hatsukami Dorothy K.
Published: August 2024

Supplementary Table 2. Regression models with covariates for the association between days since last smoked cigarettes and BOPH among people who used to smoke cigarettes exclusively and people who currently use e-cigarettes
Supplemental Figure 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Authors: Smeltzer Matthew P. , Akinbobola Olawale A. , Ray Meredith A. , Fehnel Carrie , Saulsberry Andrea , Dortch Kourtney R. , Pimenta Kelly , Matthews Anberitha T. , Osarogiagbon Raymond U.
Published: August 2024

Supplemental Figure 1: Variation in EGFR and PDL1 testing in the Mid-south Quality of Surgical Resection cohort by Patient-, Provider-, and Institutional-level factors spanning a four year period including the first two years of FDA approval of Osimertinib for adjuvant therapy in non-small cell lung cancer 2018 to 2022. Significant results at the 0.05 level are denoted (*) for EGFR and (^) for PDL1. CoC, Commission on Cancer; ACCP, Academic Comprehensive Cancer Program; CCP, Comprehensive Community Cancer Program.
Supplementary Table S5 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Authors: Rahman Md. Shafiur , Rahman Md. Mahfuzur , Acharya Kiran , Haruyama Rei , Shah Richa , Matsuda Tomohiro , Inoue Manami , Abe Sarah K.
Published: August 2024

Supplementary Table S5 shows the results of a logistic regression model identifying the risk factors associated with cervical cancer testing uptake within the last five years
Table S9 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Authors: Ruffieux Yann , Fernández Villalobos Nathalie V. , Didden Christiane , Haas Andreas D. , Chinogurei Chido , Cornell Morna , Egger Matthias , Maartens Gary , Folb Naomi , Rohner Eliane
Published: August 2024

Table S9 shows hazard ratios for prostate cancer diagnosis, with no left-truncation at first HIV indicator.
Supplemental Table 5 from Association of Urinary Biomarkers of Tobacco Exposure with Lung Cancer Risk in African American and White Cigarette Smokers in the Southern Community Cohort Study
Authors: Murphy Sharon E. , Guillermo Cherie , Thomson Nicole M. , Carmella Steven G. , Wittmann Milo , Aldrich Melinda C. , Cai Qiuyin , Sullivan Shannon M. , Stram Daniel O. , Le Marchand Loïc , Hecht Stephen S. , Blot William J. , Park S. Lani
Published: August 2024

Supplemental Table 5. Geometric mean of Biomarkers by Race/Ethnicity Controls and in the overall study
Supplemental Table 2 from Association of Urinary Biomarkers of Tobacco Exposure with Lung Cancer Risk in African American and White Cigarette Smokers in the Southern Community Cohort Study
Authors: Murphy Sharon E. , Guillermo Cherie , Thomson Nicole M. , Carmella Steven G. , Wittmann Milo , Aldrich Melinda C. , Cai Qiuyin , Sullivan Shannon M. , Stram Daniel O. , Le Marchand Loïc , Hecht Stephen S. , Blot William J. , Park S. Lani
Published: August 2024

Supplemental Table 2. Median and SD of the log distribution for smoking-related urinary biomarkers overall
Table S5 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Authors: Ruffieux Yann , Fernández Villalobos Nathalie V. , Didden Christiane , Haas Andreas D. , Chinogurei Chido , Cornell Morna , Egger Matthias , Maartens Gary , Folb Naomi , Rohner Eliane
Published: August 2024

Table S5 shows characteristics at diagnosis of prostate cancer, by population group.
Table 1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Authors: Ruffieux Yann , Fernández Villalobos Nathalie V. , Didden Christiane , Haas Andreas D. , Chinogurei Chido , Cornell Morna , Egger Matthias , Maartens Gary , Folb Naomi , Rohner Eliane
Published: August 2024

Cohort characteristics by HIV status and overall.
Table S2 from Mammographic Texture versus Conventional Cumulus Measure of Density in Breast Cancer Risk Prediction: A Literature Review
Authors: Ye Zhoufeng , Nguyen Tuong L. , Dite Gillian S. , MacInnis Robert J. , Hopper John L. , Li Shuai
Published: August 2024

Table S2 shows the discrepancies in the image conditions of the mammograms that were used for performance analysis. The image conditions include the types of mammograms (FFDM/SFM), view of the mammogram (CC/MLO), digitizing machine (SFM only) or digital machine (FFDM only), regions of interest, and grey level and size of the pixels.
Supplementary Table 3. from Joint Associations of Diet and Device-Measured Physical Activity with Mortality and Incident CVD and Cancer: A Prospective Analysis of the UK Biobank Study
Authors: Inan-Eroglu Elif , Ahmadi Matthew , Biswas Raaj Kishore , Ding Ding , Rezende Leandro F.M. , Lee I-Min , Giovannucci Edward L. , Stamatakis Emmanuel
Published: August 2024

Supplementary Table 3 shows the interactions between physical activity and diet quality score for all-cause mortality, cardiovascular disease, total cancer, and physical activity, diet, and adiposity-related cancer incidence.
Supplementary Figure 8 from Joint Associations of Diet and Device-Measured Physical Activity with Mortality and Incident CVD and Cancer: A Prospective Analysis of the UK Biobank Study
Authors: Inan-Eroglu Elif , Ahmadi Matthew , Biswas Raaj Kishore , Ding Ding , Rezende Leandro F.M. , Lee I-Min , Giovannucci Edward L. , Stamatakis Emmanuel
Published: August 2024

Joint dose-response association between physical activity volume (minutes/day), diet quality score with all-cause mortality.Supplementary Figure 8 shows the joint dose-response association between physical activity volume (minutes/day) and diet quality score with respect to all-cause mortality.
Supplemental Table S2 from Rural–Urban Cancer Incidence and Trends in the United States, 2000 to 2019
Authors: Semprini Jason , Gadag Khyathi , Williams Gawain , Muldrow Aniyah , Zahnd Whitney E.
Published: August 2024

Supplemental Table S2: Age-adjusted invasive cancer incidence rates and corresponding 95% confidence intervals per 100,000 by primary site, rural status, and sex, 2015 to 2019
Supplementary Figure 11 from Joint Associations of Diet and Device-Measured Physical Activity with Mortality and Incident CVD and Cancer: A Prospective Analysis of the UK Biobank Study
Authors: Inan-Eroglu Elif , Ahmadi Matthew , Biswas Raaj Kishore , Ding Ding , Rezende Leandro F.M. , Lee I-Min , Giovannucci Edward L. , Stamatakis Emmanuel
Published: August 2024

Joint dose-response association between physical activity volume (minutes/day), diet quality score with physical activity, diet and adiposity related cancer incidence.Supplementary Figure 11 shows the joint dose-response association between physical activity volume (minutes/day) and diet quality score with respect to physical activity, diet and adiposity related cancer incidence.
Data from Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms
Authors: Davidson Natalie R. , Barnard Mollie E. , Hippen Ariel A. , Campbell Amy , Johnson Courtney E. , Way Gregory P. , Dalley Brian K. , Berchuck Andrew , Salas Lucas A. , Peres Lauren C. , Marks Jeffrey R. , Schildkraut Joellen M. , Greene Casey S. , Doherty Jennifer A.
Published: August 2024

AbstractBackground:
High-grade serous carcinoma (HGSC) gene expression subtypes are associated with differential survival. We characterized HGSC gene expression in Black individuals and considered whether gene expression differences by self-identified race may contribute to poorer HGSC survival among Black versus White individuals.
Methods:
We included newly generated RNA sequencing data from Black and White individuals and array-based genotyping data from four existing studies of White and Japanese individuals. We used K-means clustering, a method with no predefined number of clusters or dataset-specific features, to assign subtypes. Cluster- and dataset-specific gene expression patterns were summarized by moderated t-scores. We compared cluster-specific gene expression patterns across datasets by calculating the correlation between the summarized vectors of moderated t-scores. After mapping to The Cancer Genome Atlas–derived HGSC subtypes, we used Cox proportional hazards models to estimate subtype-specific survival by dataset.
Results:
Cluster-specific gene expression was similar across gene expression platforms and racial groups. Comparing the Black population with the White and Japanese populations, the immunoreactive subtype was more common (39% vs. 23%–28%) and the differentiated subtype was less common (7% vs. 22%–31%). Patterns of subtype-specific survival were similar between the Black and White populations with RNA sequencing data; compared with mesenchymal cases, the risk of death was similar for proliferative and differentiated cases and suggestively lower for immunoreactive cases [Black population HR = 0.79 (0.55, 1.13); White population HR = 0.86 (0.62, 1.19)].
Conclusions:
Although the prevalence of HGSC subtypes varied by race, subtype-specific survival was similar.
Impact:
HGSC subtypes can be consistently assigned across platforms and self-identified racial groups.
Data from Kidney Cancer Incidence among Non-Hispanic American Indian and Alaska Native Populations in the United States, 1999 to 2020
Authors: Melkonian Stephanie C. , Jim Melissa A. , Haverkamp Donald , Lee Madeleine , Janitz Amanda E. , Campbell Janis E.
Published: August 2024

AbstractBackground:
Non-Hispanic American Indian and Alaska Native (NH-AI/AN) people exhibit a disproportionate incidence of kidney cancer. Nationally aggregated data do not allow for a comprehensive description of regional disparities in kidney cancer incidence among NH-AI/AN communities. This study examined kidney cancer incidence rates and trends among NH-AI/AN compared with non-Hispanic White (NHW) populations by geographic region.
Methods:
Using the United States Cancer Statistics American Indian and Alaska Native (AI/AN) Incidence Analytic Database, age-adjusted incidence rates (per 100,000) of kidney cancers for NH-AI/AN and NHW people for the years 2011 to 2020 combined using surveillance, epidemiology, and end Results (SEER)∗stat software. Analyses were restricted to non-Hispanic individuals living in purchased/referred care delivery area (PRCDA) counties. Average annual percent changes (AAPCs) and trends (1999–2019) were estimated using Joinpoint regression analyses.
Results:
Rates of kidney cancer incidence were higher among NH-AI/AN compared with NHW persons in the United States overall and in five of six regions. Kidney cancer incidence rates also varied by region, sex, age, and stage of diagnosis. Between 1999 and 2019, trends in kidney cancer rates significantly increased among NH-AI/AN males (AAPC = 2.7%) and females (AAPC = 2.4%). The largest increases were observed for NH-AI/AN males and females aged less than 50 years and those diagnosed with localized-stage disease.
Conclusions:
Study findings highlight growing disparities in kidney cancer incidence rates between NH-AI/AN and NHW populations.
Impact:
Differences in geographic region, sex, and stage highlight the opportunities to decrease the prevalence of kidney cancer risk factors and improve access to preventive care.
Data from Association of Urinary Biomarkers of Tobacco Exposure with Lung Cancer Risk in African American and White Cigarette Smokers in the Southern Community Cohort Study
Authors: Murphy Sharon E. , Guillermo Cherie , Thomson Nicole M. , Carmella Steven G. , Wittmann Milo , Aldrich Melinda C. , Cai Qiuyin , Sullivan Shannon M. , Stram Daniel O. , Le Marchand Loïc , Hecht Stephen S. , Blot William J. , Park S. Lani
Published: August 2024

AbstractBackground:
After accounting for smoking history, lung cancer incidence is greater in African Americans than Whites. In the multiethnic cohort, total nicotine equivalents (TNE) are higher in African Americans than Whites at similar reported cigarettes per day. Greater toxicant uptake per cigarette may contribute to the greater lung cancer risk of African Americans.
Methods:
In a nested case–control lung cancer study within the Southern Community Cohort, smoking-related biomarkers were measured in 259 cases and 503 controls (40% White; 56% African American). TNE, the trans-3-hydroxycotinine/cotinine ratio, 4-(methylnitrosamino)-1–3-(pyridyl)-1-butanol (NNAL), mercapturic acid metabolites of volatile organic compounds, phenanthrene metabolites, cadmium (Cd), and (Z)-7-(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopenyl]hept-5-enoic acid were quantified in urine. Unconditional logistic regression was used to estimate the ORs and 95% confidence intervals (CI) for each biomarker and lung cancer risk.
Results:
TNE, NNAL, and Cd were higher in cases than controls (adjusted for age, race, sex, body mass index, and cigarettes per day). Among cases, these levels were higher in African Americans compared with Whites. After accounting for age, sex, body mass index, and pack-years, a one-SD increase in log-TNE (OR = 1.30; 95% CI, 1.10–1.54) and log-NNAL (OR = 1.27; 95% CI, 1.03–1.58 with TNE adjustment) was associated with lung cancer risk. In this study, in which NNAL concentration is relatively high, the association for log-TNE was attenuated after adjustment for log-NNAL.
Conclusions:
Smoking-related biomarkers provide additional information for lung cancer risk in smokers beyond smoking pack-years.
Impact:
Urinary NNAL, TNE, and Cd concentrations in current smokers, particularly African American smokers, may be useful for predicting lung cancer risk.
HPV Extended Genotyping to Triage Abnormal Cervical Cancer Screens—Balancing the Harms and Benefits of an Additional Triage Test before Direct Colposcopy Referral
Authors: Gottschlich Anna , Smith Laurie W. , Proctor Lily , Ogilvie Gina S.
Published: August 2024

The Netherlands’ cervical cancer screening program transitioned to primary human papillomavirus (HPV) screening in 2017. After the introduction of HPV-based screening, the country saw increases in colposcopy referral rates and detections of low-grade lesions. In July 2022, genotyping was introduced, and those with borderline or mild dyskaryotic (BMD) cytologic abnormalities were only referred to colposcopy if positive for HPV type 16 or 18, and repeat screening otherwise. In this article, various strategies using extended genotyping (HPV16/18/31/33/45/52/58) as a triage test after an abnormal screen were explored using data from HPV-positive participants with normal or BMD cytology in the Population-Based Screening Study Amsterdam (POBASCAM) trial. The authors assessed positive and negative predictive values and colposcopy referral rates for each strategy using extended genotyping to triage women to either direct referral to colposcopy or repeat screening. Direct referral did not meet positive and negative predictive value thresholds for efficiency for any strategies. However, the authors note that direct referral may nonetheless be useful among those with BMD due to minimal increases in colposcopy referrals and concerns of loss to follow-up at repeat screening. These findings demonstrate the potential utility of extended genotyping as a triage test in primary HPV screening programs. The results should be considered alongside the fact that referral to repeat screening may result in loss of engagement of women who need treatment to prevent invasive cancer.

See related article by Kroon et al., p. 1037
Supplementary Fig. S4 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Authors: Embaby Alaa , Huijberts Sanne C.F.A. , Wang Liqin , Leite de Oliveira Rodrigo , Rosing Hilde , Nuijen Bastiaan , Sanders Joyce , Hofland Ingrid , van Steenis Charlaine , Kluin Roelof J.C. , Lieftink Cor , Smith Christopher G. , Blank Christian U. , van Thienen Johannes V. , Haanen John B.A.G. , Steeghs Neeltje , Opdam Frans L. , Beijnen Jos H. , Huitema Alwin D.R. , Bernards Rene , Schellens Jan H.M. , Wilgenhof Sofie
Published: August 2024

Supplementary Fig. S4. Vorinostat O-glucuronide plasma concentrations over time on days 1 and 14 of the first treatment cycle.
Supplementary Table S4 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Association between plasma protein levels and risk of MPN or MDS/AML.
Supplementary Table S2 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Association between protein levels (N=1,463), myeloid neoplasm (MN) risk and clonal hematopoesisis (CH).
Supplementary Figure S5 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Association between plasma proteins and CH genes with or without blood count correction.
Supplementary Figure 4 from Mapping the Single-Cell Differentiation Landscape of Osteosarcoma
Authors: Truong Danh D. , Weistuch Corey , Murgas Kevin A. , Admane Prasad , King Bridgette L. , Chauviere Lee Jes , Lamhamedi-Cherradi Salah-E. , Swaminathan Jyothishmathi , Daw Najat C. , Gordon Nancy , Gopalakrishnan Vidya , Gorlick Richard G. , Somaiah Neeta , Deasy Joseph O. , Mikos Antonios G. , Tannenbaum Allen , Ludwig Joseph
Published: August 2024

Cell cycle score for each cluster in the MTL
Supplemental Table 1 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
Authors: Haddad Tufia C. , Suman Vera J. , Giridhar Karthik V. , Sideras Kostandinos , Northfelt Donald W. , Ernst Brenda J. , O’Sullivan Ciara C. , Singh Ravinder J. , Desta Zeruesenay , Peethambaram Prema P. , Hobday Timothy J. , Chumsri Saranya , Leon-Ferre Roberto A. , Ruddy Kathryn J. , Yadav Siddhartha , Taraba Jodi L. , Goodnature Barbara , Goetz Matthew P. , Wang Liewei , Ingle James N.
Published: August 2024

Supplemental Table 1: Dose limiting toxicities for run-in phase of ANA10.
Supplementary Table S6 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

Representativeness of Study Participants
Supplementary Methods S1 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

Supplementary Methods
Supplementary Figure S7 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

The 5hmC diagnostic model for CRC/AA detects stage I-III CRC missed by CEA in the external validation set.
Table S2 from Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma
Authors: Zhang Zufei , Zhang Daping , Guo Wenchuan , Fenton Keenan , Narayanan Sujata , Jain Shweta , Jiang Joy , Castellino Sharon M. , Kelly Kara M. , Cole Peter D. , Keller Frank G. , Garg Amit , Chia Yen Lin
Published: August 2024

Exposure metrics of ADC and MMAE following intravenous administration of brentuximab vedotin 1.8 mg/kg Q3W at steady state by age subgroup in the PK subpopulation.
Figure S3 from Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma
Authors: Zhang Zufei , Zhang Daping , Guo Wenchuan , Fenton Keenan , Narayanan Sujata , Jain Shweta , Jiang Joy , Castellino Sharon M. , Kelly Kara M. , Cole Peter D. , Keller Frank G. , Garg Amit , Chia Yen Lin
Published: August 2024

Comparison of cycle 1 Cave for ADC and MMAE exposures in patients with grade ≥2 or grade ≥3 PN and patients without grade ≥2 or grade ≥3 PN in the PK subpopulation.
Supplementary Table S2 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplementary Table S2: Matrisome and adhesome cluster membership.
Supplementary Table S4 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Authors: Nguyen Charles B. , Reimers Melissa A. , Perera Chamila , Abida Wassim , Chou Jonathan , Feng Felix Y. , Antonarakis Emmanuel S. , McKay Rana R. , Pachynski Russell K. , Zhang Jingsong , Reichert Zachery R. , Palmbos Phillip L. , Caram Megan E.V. , Vaishampayan Ulka N. , Heath Elisabeth I. , Hopkins Alexander C. , Cieslik Marcin P. , Wu Yi-Mi , Robinson Dan R. , Baladandayuthapani Veerabhadran , Chinnaiyan Arul M. , Alva Ajjai S.
Published: August 2024

Supplementary Table S4. External somatic CDK12 sequencing and NGS reports.
Data from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Authors: Schmidt Iris , Zhao Xiaojuan , van der Waaij Anne M. , Meersma Gert Jan , Dijkstra Frederieke A. , Haveman Jan Willem , van Etten Boudewijn , Robinson Dominic J. , Kats-Ugurlu Gursah , Nagengast Wouter B.
Published: August 2024

AbstractPurpose:
The ability to identify residual tumor tissues in patients with locally advanced esophageal cancer following neoadjuvant chemoradiotherapy (nCRT) is essential for monitoring the treatment response. Using the fluorescent tracer bevacizumab-800CW, we evaluated whether ultrasound-guided quantitative fluorescent molecular endoscopy (US-qFME), which combines quantitative fluorescence molecular endoscopy (qFME) with ultrasound-guided needle biopsy/single-fiber fluorescence (USNB/SFF), can be used to identify residual tumor tissues in patients following nCRT.
Experimental Design:
Twenty patients received an additional endoscopy procedure the day before surgery. qFME was performed at the primary tumor site (PTS) and in healthy tissue to first establish the optimal tracer dose. USNB/SFF was then used to measure intrinsic fluorescence in the deeper PTS layers and lymph nodes (LN) suspected for metastasis. Finally, the intrinsic fluorescence and the tissue optical properties—specifically, the absorption and reduced scattering coefficients—were combined into a new parameter called omega.
Results:
First, a 25-mg bevacizumab-800CW dose allowed for clear differentiation between the PTS and healthy tissue, with a target-to-background ratio (TBR) of 2.98 (IQR, 1.86–3.03). Moreover, we found a clear difference between the deeper esophageal PTS layers and suspected LN compared to healthy tissues, with TBR values of 2.18 and 2.17, respectively. Finally, our new parameter, omega, further improved the ability to differentiate between the PTS and healthy tissue.
Conclusions:
Combining bevacizumab-800CW with US-qFME may serve as a viable strategy for monitoring the response to nCRT in esophageal cancer and may help stratify patients regarding active surveillance versus surgery.
Data from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
Authors: Haddad Tufia C. , Suman Vera J. , Giridhar Karthik V. , Sideras Kostandinos , Northfelt Donald W. , Ernst Brenda J. , O’Sullivan Ciara C. , Singh Ravinder J. , Desta Zeruesenay , Peethambaram Prema P. , Hobday Timothy J. , Chumsri Saranya , Leon-Ferre Roberto A. , Ruddy Kathryn J. , Yadav Siddhartha , Taraba Jodi L. , Goodnature Barbara , Goetz Matthew P. , Wang Liewei , Ingle James N.
Published: August 2024

AbstractPurpose:
We previously reported that postmenopausal women with estrogen receptor-α–positive breast cancer receiving adjuvant anastrozole 1 mg/day (ANA1) with estrone (E1) ≥1.3 pg/mL and estradiol (E2) ≥0.5 pg/mL [inadequate estrogen suppression (IES)] had a threefold increased risk of a breast cancer event. The objective of this study was to determine if increasing anastrozole to 10 mg/day (ANA10) could result in adequate estrogen suppression (AES: E1 <1.3 pg/mL and/or E2 <0.5 pg/mL) among those with IES on ANA1.
Patients and Methods:
Postmenopausal women with estrogen receptor-α–positive breast cancer planning to receive adjuvant ANA1 were eligible. E1 and E2 were assessed pre- and post-8 to 10 weeks of ANA1. Those with IES were switched to 8- to 10-week cycles of ANA10 followed by letrozole 2.5 mg/day. E1 and E2 were assessed after each cycle. Anastrozole concentrations were measured post-ANA1 and post-ANA10. Primary analyses included patients who documented taking at least 80% of the planned treatment (adherent cohort).
Results:
In total, 132 (84.6%) of 156 eligible patients were ANA1 adherent. IES occurred in 40 (30.3%) adherent patients. Twenty-five (78.1%) of 32 patients who began ANA10 were adherent, and AES was achieved in 19 (76.0%; 90% confidence interval, 58.1%–89.0%) patients. Anastrozole concentrations post-ANA1 and post-ANA10 did not differ by estrogen suppression status among adherent patients. AES was maintained/attained in 21 (91.3%) of 23 letrozole-adherent patients.
Conclusions:
Approximately 30% of ANA1-adherent patients had IES. Among those who switched to ANA10 and were adherent, 76% had AES. Further studies are required to validate emerging data that ANA1 results in IES for some patients and to determine the clinical benefit of switching to ANA10 or an alternative aromatase inhibitor.
Data from Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma
Authors: Zhang Zufei , Zhang Daping , Guo Wenchuan , Fenton Keenan , Narayanan Sujata , Jain Shweta , Jiang Joy , Castellino Sharon M. , Kelly Kara M. , Cole Peter D. , Keller Frank G. , Garg Amit , Chia Yen Lin
Published: August 2024

AbstractPurpose:
The purpose of the study was to evaluate the relationships between brentuximab vedotin (BV) pharmacokinetics, age, and body weight (BW) with efficacy and safety in pediatric and young adult patients with previously untreated, high-risk classical Hodgkin lymphoma in the phase III AHOD1331 study.
Experimental Design:
Overall, 296 patients (age 2–21 years) in the overall population were randomized to and received BV + chemotherapy; the pharmacokinetic subpopulation comprised 24 patients (age <13 years). Age- and/or BW-based (pharmacokinetic surrogates) subgroup analyses of efficacy and safety were conducted for the overall population. Exposure–response analyses were limited to the pharmacokinetic subpopulation.
Results:
There were no visible trends in disease characteristics across pediatric age subgroups, whereas BW increased with age. Observed antibody–drug conjugate exposures in patients ages <12 years were lower than those in adults administered BV 1.8 mg/kg every 3 weeks, as exposure increased with BW. Nevertheless, no detrimental impact on event-free survival was seen in younger subgroups: 3-year event-free survival rates were 96.2% (2–<12 years) and 92.0% (12–<18 years), with no events observed in those ages <6 years. Neither early response nor lack of need for radiation therapy was associated with high pharmacokinetic exposure. No evidence of exposure-driven grade ≥2 or ≥3 peripheral neuropathy or grade ≥3 neutropenia was seen in exposure-safety and BW-based subgroup analyses; the incidence of these safety events was comparable across pediatric age subgroups, despite lower exposure in younger children.
Conclusions:
No further adjustments based on age or BW are required for the BV dosage (1.8 mg/kg every 3 weeks) approved in children.
Supplementary Figure S4 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
Authors: Bratti Manuela , Stubbs Elisa , Kolodych Sergii , Souchet Herve , Kelly Lois , Merlin Johanna , Marchal Michelle , Castellano Remy , Josselin Emmanuelle , Pasquer Hélène , Benajiba Lina , Puissant Alexandre , Koniev Oleksandr , Collette Yves , Belanger Coralie , Hermine Olivier , Monteiro Renato C. , Launay Pierre
Published: August 2024

Figure S4
Supplementary Figure S1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
Authors: Bratti Manuela , Stubbs Elisa , Kolodych Sergii , Souchet Herve , Kelly Lois , Merlin Johanna , Marchal Michelle , Castellano Remy , Josselin Emmanuelle , Pasquer Hélène , Benajiba Lina , Puissant Alexandre , Koniev Oleksandr , Collette Yves , Belanger Coralie , Hermine Olivier , Monteiro Renato C. , Launay Pierre
Published: August 2024

Figure S1
Supplemental Figure S7 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Authors: Collins Victor J. , Ludwig Katelyn R. , Nelson Ariana E. , Sundara Rajan Soumya , Yeung Choh , Vulikh Ksenia , Isanogle Kristine A. , Mendoza Arnulfo , Difilippantonio Simone , Karim Baktiar O. , Caplen Natasha J. , Heske Christine M.
Published: August 2024

Etoposide combined with DNA-PK inhibition induces apoptosis in TP53 wild-type and mutant Ewing sarcoma cell lines
Supplementary Table 1 from SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity
Authors: Fang Nan , Liu Bing , Pan Qiuzhong , Gong Tingting , Zhan Meixiao , Zhao Jingjing , Wang Qijing , Tang Yan , Li Yongqiang , He Jia , Xiang Tong , Sun Fengze , Lu Ligong , Xia Jianchuan
Published: August 2024

Supplementary Table 1